Search Results

cells and platelets, revealing significant findings that enhance our understanding of GPCRs' roles in immune Additionally, the study identified unique expression patterns of GPCRs in different immune cell types immune responses and highlights the need for further functional studies to elucidate their specific also opens doors for exploring the roles of these receptors in various pathological states, including cancer Therefore this study significantly advances our understanding of GPCR expression in human immune cells

July 2022 Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate into clinical trials "HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers biopharmaceutical company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development, and Cancer Research UK, the world’s largest private funder of cancer research, today announce the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial."

September 2022 "Background: Colorectal cancer is the third most common cancer and requires more prognostic The clinical significance of GPR39 in colon cancer has never been reported. Materials: In our study, we compared GPR39 expression between colon cancers and tumor-adjacent tissues by retrieving TCGA data and detected the expression of GPR39 in colon cancers with qPCR and immunohistochemistry

Therefore, GPCRs are potential targets for cancer immunotherapy. Additionally, we focus on the roles of GPCRs in regulating immune checkpoint proteins involved in immune Finally, we review the progress of clinical trials of GPCR-targeted drugs for cancer treatment, which Authors Guang-Hong Qiu, Bin Yu, Mei Ma Tags GPCRs , cancer immune checkpoints , cancer immunotherapy , immune cells , tumor microenvironment .

< GPCR News < GPCRs in Oncology and Immunology Chemokine Physiology in Cancer Published date November cancer cells out of the tumor as well as immigration of tumor infiltrating immune cells that culminate in a tumor unique immune microenvironment. Facets of chemokine physiology across discrete cancer immune phenotypes are contrasted to existing chemokine-centered therapies in cancer.

< GPCRs in Oncology and Immunology The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure Published date June 12, 2023 Abstract "Immune checkpoint blockade (ICB) targeting PD-1 and CTLA-4 has revolutionized cancer treatment. However, many cancers do not respond to ICB, prompting the search for additional strategies to achieve These data indicate that Gαs-GPCRs are druggable immune checkpoints that might be targeted to enhance